HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Inc.

www.pfizer.com

Latest From Pfizer Inc.

Tesaro's On The Right Path With Anti-PD-1 Dostarlimab In Endometrial Cancer

Interview: Tesaro Chief Medical Officer Martin Huber addresses dostarlimab GARNET data and provides an update on integration with GlaxoSmithKline.

Research & Development Cancer

Generic Industry Market Forces May Impact GDUFA III Talks

AAM's Chip Davis said a user fee cut is not in order, but industry consolidation and product launch problems may mean it cannot accept another large increase.
Generic Drugs FDA

Why Biogen/Eisai's Aducanumab Failure Is Not The End Of Amyloid Hypothesis

Biogen and Eisai still have multiple programs testing amyloid-targeting therapies in the treatment of Alzheimer's disease, but pressure for Biogen to focus its efforts elsewhere are mounting after the partners discontinued Phase III studies for aducanumab.

Clinical Trials Neurology

AESGP Conference Round-Up: Digital Disruption, Med Device Worries And The Benefits Of Switching

Speakers from the EMA and European Commission, as well as Pfizer and HRA Pharma, debated at the AESGP's Regulatory Conference the ongoing digital transformation of the European consumer healthcare market, the latest developments in the implementation of the new medical devices regulations, and the best ways to encourage Rx-to-OTC switching across the EU.
Europe Health
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register